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Introduction {#sec1}
============

Long-term functionally multipotent mouse hematopoietic stem cells (HSCs), as defined by engraftment following primary and secondary transplantation, are found within a phenotypic CD34^−/low^Flt3^−^c-Kit^+^Sca-1^+^Lineage^−^ (CD34^−^KSL) bone marrow (BM) cell population ([@bib14]). Functional HSCs can be further enriched using CD150 expression ([@bib12], [@bib13]). However, even the most phenotypically "pure" HSC population remains functionally heterogeneous in terms of lineage output and self-renewal capacity ([@bib20]). For example, HSCs display heterogeneity in blood reconstitution duration and are commonly resolved into short-term (ST), intermediate-term (IT), and long-term (LT) repopulating HSCs ([@bib21]).

HSC multipotency has been traditionally defined by neutrophil/monocyte (nm) and B/T lymphocyte (B/T) differentiation. However, without considering the contribution to erythrocytes (E) and platelets (P), such definitions only partially describe HSC multipotency. As the two most abundant and essential blood cell components, understanding E and P lineage contribution is also of significance in the development of strategies to improve clinical BM transplantation. Using clonal analysis in combination with five-blood lineage (nm, B, T, E and P) analysis, we previously determined the functional heterogeneity of the phenotypic HSC (pHSC) compartment in young mice ([@bib21]). In doing so, we identified a subset of pHSCs that were functionally myeloid-restricted repopulating progenitors (MyRPs). Using paired-daughter cell analysis, we further demonstrated MyRPs could be directly generated from HSCs via a myeloid-bypass pathway through a single-cell division event.

While the majority of MyRPs in young mice were ST/IT-MyRPs, a minor population was LT-MyRPs (engrafting in secondary recipients), suggesting that MyRPs may resolve into distinct subpopulations. Further evidence for this comes from an independent analysis of HSCs at five-blood-lineage resolution ([@bib3]). Through using a *Vwf-mCherry* reporter mouse line, Carrelha et al. identified a population of potently self-renewing HSCs within the CD150^+^CD34^−^KSL population that had myeloid and lymphoid capacity (in the context of *in vitro* differentiation assays) but displayed P-restricted output *in vivo* (in primary and secondary transplantation assays). In young mice, this population of P-restricted HSCs appeared to be a minor subset of the phenotypic CD150^+^CD34^−^KSL population (just ∼2%). According to our previously defined criteria, these P-restricted HSCs would be LT-MyRPs, which we observed at similar frequencies within our own transplantation assays ([Table S1](#mmc1){ref-type="supplementary-material"}). These data suggest that ST-MyRPs and LT-MyRPs must be considered as distinct populations within the pHSC compartment.

Native hematopoiesis has also recently been investigated at five-blood-lineage resolution ([@bib15]). Through elegant transposon-based barcoding experiments, Rodriguez-Fraticelli et al. found that pHSCs were a major source of the megakaryocyte/P lineage. These data are highly consistent with the presence of MyRPs and activity of the myeloid-bypass pathway in native hematopoiesis. Further evidence for direct differentiation of HSCs into MyRPs came from HSC cell-division counting experiments by Bernitz et al., which suggested that MyRP-like cells were generated from LT-HSCs after four symmetric self-renewal cell division events ([@bib2]).

Dysfunction within the HSC compartment is thought to be a key mechanism underlying age-related hematopoietic perturbations ([@bib5]). Aged HSCs are reported to show altered self-renewal ([@bib1], [@bib4], [@bib18]), impaired homing and engraftment upon transplantation ([@bib4]), myeloid-biased differentiation ([@bib4], [@bib18]), P-biased differentiation ([@bib8]), and megakaryocytic/erythroid-biased gene expression patterns ([@bib16]). However, most of these observations have been made using population-based methods using only three- (or four)-lineage analysis. Here, we have defined how the pHSC compartment changes during aging at five-blood-lineage resolution. From over 400 clonal transplantation experiments, we demonstrate there is a large increase in MyRP frequency with age. A modest increase in the frequency of functional HSCs within the BM was also observed. Unexpectedly, we also identified a subset of functional cells within the aged pHSC compartment that generated only myeloid (P, E, and/or nm) cells in primary recipients but displayed multipotent (P, E, nm, T, and B) output in secondary recipients. We termed this age-specific functional cell type latent-HSCs. Our clonal analysis of HSC aging therefore questions the current dogma of HSC compartment aging and current approaches to define HSC function.

Results {#sec2}
=======

Aging Is Associated with Altered Functional HSC Composition and an Expanded MyRP Population {#sec2.1}
-------------------------------------------------------------------------------------------

To directly compare HSC heterogeneity during aging, it was first important to define pHSCs regardless of age. Young and aged functional HSCs are reportedly enriched in the CD150^+^CD48^−^ gate of the CD34^−^KSL population ([@bib22]). To purify HSCs, we used Sca-1^high^ cells within the KSL population, since Sca-1^low^ cells do not contain functional HSCs ([@bib20]). With this HSC gating strategy, 97% of the (CD34^−^KSL) HSC compartment in young (8- to 12-week-old) and aged (20- to 24-month-old) mice were negative for CD48 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). These data suggested that CD48 staining was not essential to purify functional HSCs both in young and aged mice. Consistent with previous studies ([@bib18]), the BM frequency of the pHSC (CD34^−^KSL) compartment increased ∼10-fold in aged mice ([Figures 1](#fig1){ref-type="fig"}A and 1B).Figure 1The Phenotypic HSC Compartment Changes with Age(A) Representative flow cytometric data of young and aged bone marrow (BM): MPP, multipotent progenitor; LMPP, lymphoid-primed multipotent progenitor; Fr 1, fraction 1; Fr 2, fraction 2; Fr 3, fraction 3.(B) Frequency of the HSC/MPP population (left) and HSC subpopulations (right) in young and aged BM (as detailed in A). Dots represent individual mice, and horizontal lines indicate median ± SD.(C) Summary of primary and secondary transplantation experiments to test potential of young and aged single phenotypic HSCs. Single CD34^−^KSL, fraction 1, fraction 2, or fraction 3 cells were sorted from BM cells of Kusabira Orange (KuO) mice and were individually transplanted with 2 × 10^5^ BM competitor cells from Ly5.1/Ly5.2-F1 mice into lethally irradiated Ly5.2 mice. Chimerism of KuO^+^ neutrophils/monocytes, erythrocytes, platelets, B cells, and T cells in peripheral blood (PB) was analyzed at 2, 3, 4, 8, (12), 16, (20), and 24 weeks after primary transplantation. Secondary transplantation assays were performed by transferring 1 × 10^7^ whole BM cells from primary recipient mice. PB chimerism was analyzed 4, 12, 16, 20, (and 21--22) weeks in secondary recipients.(D) PB chimerism of individual single young and aged HSCs in a total of 421 primary recipients (as described in C), separated based on lineage output.(E) Estimated frequency of functional HSCs, CMRPs, MERPs, MkRPs, and "other" within the young and aged pHSC compartment, derived from single-cell transplantation assays ([Table 1](#tbl1){ref-type="table"}). CMRPs, MERPs, and MkRPs are subsets of MyRPs. "Non-reconstituting" denotes no PB reconstitution of KuO^+^ cells in primary recipients.

We previously resolved the CD150^+^CD34^−^KSL pHSCs population in young mice into two fractions based on CD41 expression: fraction 1 (CD150^+^CD41^−^CD34^−^KSL) cells were enriched for functionally multipotent LT/IT-reconstituting HSCs, whereas fraction 2 (CD150^+^CD41^+^CD34^−^KSL) cells tended to show a myeloid-committed phenotype. By contrast, CD150^−^CD41^−^CD34^−^KSL (termed fraction 3) cells were predominantly ST-reconstituting HSCs. Within the pHSC compartment, the frequency of CD150^+^CD41^−^CD34^−^KSL (fraction 1) cells, in which most young functional HSCs are found ([@bib21]), was significantly decreased in aged mice. By contrast, the frequency of CD150^+^CD41^+^CD34^−^KSL (fraction 2) was dramatically increased (20-fold) ([Figures 1](#fig1){ref-type="fig"}A and 1B), as previously reported ([@bib6]). Smaller changes to phenotypic hematopoietic progenitor populations were also observed ([Figure S1](#mmc1){ref-type="supplementary-material"}B), in line with previous reports ([@bib5]).

To directly interrogate the functional characteristics of individual young and aged CD34^−^KSL cells, we performed single-cell transplantation into lethally irradiated young mice. We initially transplanted single CD34^−^KSL cells from young (8- to 12-week-old) and aged (20- to 24-month-old) Ly5.1 Kusabira Orange (KuO) mice ([@bib9]) into a total of 76 lethally irradiated young Ly5.2 mice, together with 2 × 10^5^ competitor cells from Ly5.1/Ly5.2-F1 mice ([Figure 1](#fig1){ref-type="fig"}C). As we observed significant changes in CD150 and CD41 expression within the CD34^−^KSL population with age, we also transplanted single CD150^+^CD41^−^CD34^−^KSL (fraction 1), CD150^+^CD41^+^CD34^−^KSL (fraction 2), and CD150^−^CD41^−^CD34^−^KSL (fraction 3) cells from young and aged mice into a total of 370 lethally irradiated Ly5.2 young mice.

We defined the 421 donor cells according to their contribution to the five peripheral blood (PB) lineages (nm, E, P, B, T) and their duration of reconstitution over 24 weeks in primary recipients, as previously defined ([@bib21]). Reconstituting cells were classified into HSC, MyRP (common myeloid repopulating progenitors \[CMRP\], megakaryocyte-erythroid repopulating progenitors \[MERP\], and megakaryocyte repopulating progenitor \[MkRP\]), and "others" (reconstituting cells that did not meet HSC- or MyRP-type reconstitution criteria) ([Figure S1](#mmc1){ref-type="supplementary-material"}D). To avoid missing functional cells, we set our threshold at 0.005%. However, similar results were seen if a threshold of 0.1% was used instead ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). By combining all single-cell transplantation datasets with the frequency of fractions 1--3 in young and aged mice, we calculated the frequency of these subsets within the pHSC compartment ([Figure 1](#fig1){ref-type="fig"}E) and in total BM ([Table S2](#mmc1){ref-type="supplementary-material"}). In terms of frequency within the pHSC population, HSCs decreased by half with age, MyRPs (including CMRPs, MERPs, and MkRPs) were found at similar frequencies, and undetectable cells (termed non-reconstituting cells) increased ([Figure 1](#fig1){ref-type="fig"}E). Functional composition was significantly different between young and aged pHSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}G; chi-square test; p \< 0.05). However, when considered as a frequency of total BM cells, HSCs increased 5.2-fold, while MyRPs expanded 13-fold ([Table S2](#mmc1){ref-type="supplementary-material"}).

LT/IT Myeloid-Restricted Repopulating Cells Expand 16-Fold with Age, Suggesting Potent Self-Renewal Capacity {#sec2.2}
------------------------------------------------------------------------------------------------------------

We next focused on the reconstitution kinetics of each repopulating cell type in primary recipients ([Figure 2](#fig2){ref-type="fig"}A). Repopulating cells (RCs) were classified based on duration of reconstitution capacity and designated as ST or LT/IT cells, as previously defined ([@bib21]). As we had seen before, most LT/IT-RCs in the young pHSC compartment were functional HSCs ([Figure 2](#fig2){ref-type="fig"}B). However, in the aged pHSC compartment, more than half of the LT/IT-RCs lacked lymphoid potential ([Figure 2](#fig2){ref-type="fig"}B), corresponding with the myeloid-biased reconstitution by aged BM cells. Strikingly, LT/IT-MyRPs expanded 16-fold within the BM with age, while ST-MyRPs expanded by a more modest 7.5-fold with age ([Table S3](#mmc1){ref-type="supplementary-material"}).Figure 2Functional Comparison of Young and Aged HSCs by Single-Cell Transplantation(A) Average chimerism of young and aged HSCs and MyRP/MySC subsets within primary recipients over 24 weeks. Functional cell types subdivided based on reconstitution duration into long-term (LT) or intermediate-term (IT) and short-term (ST) RCs. Data points indicate mean ± SD.(B) Estimated frequency of each functional cell type (HSCs, CMRPs/CMSCs, MERPs/MESCs, MkRPs/MkSCs, and "other") divided into LT/IT- and ST-repopulating subsets within the young and aged pHSC compartment, derived from single-cell transplantation assays ([Table 1](#tbl1){ref-type="table"}).(C) PB chimerism of individual single young and aged LT- and IT-HSCs in primary and secondary recipients. Blood lineage chimerism in primary recipients at 24 weeks was compared using an unpaired t test (^∗^p \< 0.05).

The dramatic increase in the frequency of LT/IT-MyRPs suggests that the P-restricted (and myeloid-restricted) HSCs described by [@bib3] likely expand with age. This is consistent with their suggestion that this population has potent self-renewal activity. Based on these data, we suggest renaming LT/IT-MyRPs. To distinguish them from multipotent LT-HSCs, ST-MyRPs, and progenitors (e.g., megakaryocyte progenitors \[MkP\], megakaryocyte-erythroid progenitors \[MEPs\], and common myeloid progenitors \[CMPs\]), we suggest naming them myeloid-restricted stem cells (MySCs), which includes megakaryocyte stem cells (MkSCs), megakaryocyte-erythroid stem cells (MESCs), and common myeloid stem cells (CMSCs) (see [Figure S2](#mmc1){ref-type="supplementary-material"} for a glossary of functional cell terminology).

Multipotent LT-HSCs Expand 3-Fold with Age but Display Reduced T-Lymphoid Potential and Limited Self-Renewal Capacity at the Clonal Level {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------

To further resolve LT- and IT-RCs, we performed secondary transplantation assays. While it was not possible to perform secondary transplantation assays on all primary recipients, we transplanted BM from 89 primary recipients (48 with young pHSCs and 41 with aged pHSCs) into a total of 153 secondary recipients ([Figure 2](#fig2){ref-type="fig"}C). We initially considered multipotent HSC reconstitution in secondary recipients. While nm, E, P, and B engraftment were comparable between young and aged LT-HSCs, T lymphoid production was significantly decreased from aged LT-HSCs in primary and secondary recipients ([Figure 2](#fig2){ref-type="fig"}C). These data confirm that even at the level of single LT-HSCs, T-potential is reduced with age. However, it is worth noting that the loss of T output was not seen in aged IT-HSCs (as compared to young IT-HSCs).

Although LT-HSCs decreased as a frequency of the pHSC compartment, we estimate the frequency within the BM increases with age 2.9-fold, from 7.3 to 21 cells per 10^6^ BM cells ([Table 1](#tbl1){ref-type="table"}). These data suggest that multipotent LT-HSCs display modest self-renewal capacity. To more directly quantify self-renewal of young LT-HSCs, we set up single-cell secondary transplantation assays from primary recipient mice displaying a functional LT-HSC phenotype following transplantation of single CD150^+^CD41^−^CD34^−^KSL (fraction 1) cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). As in our primary single-cell transplantation assays, we transplanted single CD150^+^CD41^−^CD34^−^KSL (fraction 1), CD150^+^CD41^+^CD34^−^KSL (fraction 2), and/or CD150^−^CD41^−^CD34^−^KSL (fraction 3) cells from the primary recipients into a total of 92 mice.Table 1Frequencies of Each Cell Type among Nucleated BM Cells from Secondary Transplant AssayFunctional Cell TypeYoungAgedFold IncreaseLT-HSC7.321.02.9IT-HSC5.649.99.0ST-HSC10.852.44.9LT-latent-HSC0.082.0n/aLT-CMSC0.30.0n/aIT-CMSC1.734.219.7ST-CMRP9.275.18.2LT-MESC0.30.0n/aIT-MESC0.39.127.8ST-MERP1.319.114.7LT-MkSC0.00.0n/aIT-MkSC1.220.417.1ST-MkRP6.735.15.2Other2.310.84.7Non-reconstituting cells20.3316.015.6[^4]

Consistent with our previous findings, within the primary recipient, functional HSCs and MyRPs were found within fraction 1, but MyRPs were the major cell type (59.5%) and HSCs were a more minor population (19%) ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Notably, all MyRPs displayed ST-repopulating kinetics. Fraction 3 also contained both functional HSCs and MyRPs (22.2% and 3.7%, respectively). By contrast, the only functional fraction 2 cells were MyRPs (48%) ([Figure S3](#mmc1){ref-type="supplementary-material"}C). These data suggest that single LT-HSCs can re-establish functional heterogeneity within the pHSC compartment following transplantation but with a bias toward ST-MyRP generation.

LT-RCs from the Aged BM Display a Latent-HSC Phenotype {#sec2.4}
------------------------------------------------------

To further interrogate the LT activities of MyRPs during aging, we assessed primary recipients with MyRP-type reconstitution in secondary transplantation assays. Surprisingly, aged MyRPs exhibited a phenotypic change in PB lineage output in secondary recipients; LT-RCs with myeloid-restricted reconstitution in primary recipients acquired lymphoid potential (B and/or T) in secondary recipients ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). This was seen in seven of the ten primary recipients displaying a MyRP-type reconstitution, with the remaining three not displaying LT reconstitution in secondary recipients. Strikingly, two mice with a P-restricted reconstitution pattern in the primary recipients displayed all five-blood-lineage output in secondary recipients ([Figure 3](#fig3){ref-type="fig"}B). We have termed this functional population latent-HSCs, a subpopulation of functionally multipotent HSCs that only display differentiation into a limited subset of lineage potentials during 24 weeks in primary recipients. All latent-HSCs identified in this study were from the aged CD150^+^CD41^+^CD34^−^KSL (fraction 2) population. Such a phenotype was never detected in mice transplanted with young pHSCs, both in this study and in our previous study (a total of 409 young single pHSC transplants). By contrast, LT-repopulating MySCs were detected in young BM at low frequencies ([Table 1](#tbl1){ref-type="table"}) but were not identified in aged BM.Figure 3A Subset of Aged MyRPs Display a Latent-HSC Phenotype(A) Average chimerism kinetics of young and aged LT-HSCs (n = 24 and 6, respectively), IT-HSCs (n = 24 and 10, respectively), LT-CMSCs (n = 1 and 0, respectively), IT-CMSCs (n = 7 and 3, respectively), and latent-HSCs (n = 0 and 7, respectively) using all single-cell transplantation datasets (including our data published in [@bib21]). Each line represents the frequency of donor-derived cells in the blood of a single recipient after primary transplantation and secondary transplantation.(B) Representative PB and BM chimerism in primary and secondary recipients for latent-HSCs (1--3), young LT-HSCs (4), and aged LT-HSCs (5). The frequency of KuO^+^ phenotypic stem and progenitor cells within the BM was determined at 24 weeks after primary transplantation and 20 weeks after secondary transplantation. Chimerism of KuO^+^ phenotypic HSCs, fraction 1, fraction 2, fraction 3 (highlighted in purple), MPPs, LMPPs (highlighted in blue), CMPs, GMPs, MEPs, MkPs (highlighted in gray), or CLPs (highlighted in green) is show in the bar graph. n.d. denotes no data. BM cells from mouse 1-1 and 1-2 and mouse 5-1 and 5-2 were pooled and analyzed.(C) Schematic of age-related changes to the mouse HSC compartment. Circle size/number represents the frequency of each cell type per 10^6^ BM cells. With age, the pHSC compartment expands ∼10-fold, largely due to a large increase in MyRPs/MySCs and non-reconstituting cells. Absolute numbers of functional HSCs (fHSCs) only increases modestly and therefore become less frequent within the pHSC compartment. Cumulatively, this leads to the reduced function of the HSC compartment including loss of lymphoid (B and T cell) lineage output. However, the aged pHSC compartment also contains latent HSCs, which display myeloid-restricted output in primary recipients but multipotent (five blood-lineage) output in secondary recipients. We have not detected latent-HSCs in the young pHSC compartment.

To investigate the latent-HSC phenotype further, we compared latent-HSC BM chimerism in primary and secondary recipients with that of other HSC types ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). Primary recipients of latent-HSCs as well as young and aged LT-HSCs contained CD34^−^KSL cells within the BM, which suggest that transplanted single latent-HSCs have self-renewal activity. However, immunophenotypically defined (not functionally defined) downstream hematopoietic progenitor cell (HPC) populations had significantly (p \< 0.01) lower, or no detectable, donor chimerism ([Figures 3](#fig3){ref-type="fig"}B, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). Chimerism within these HPC populations increased in the BM of secondary recipients displaying a latent-HSC phenotype. This is compatible with the output of mature blood (lymphoid) lineages in these secondary recipients. By contrast, young and aged LT-HSCs usually reconstitute BM stem and progenitor fractions in both primary and secondary recipients to the same extent ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}). These data suggest that latent-HSCs proliferate (via self-renewal that expands the CD150^+^CD41^+^CD34^−^KSL population) but largely fail to differentiate, particularly along the lymphoid lineage, within in primary recipients. However, the mechanism underlying the latent-HSC phenotype requires further clarification in future studies.

Discussion {#sec3}
==========

Here, we performed large-scale single-cell transplantation assays to investigate functional HSC heterogeneity during aging at five-blood-lineage resolution. Consistent with previous studies ([@bib4], [@bib18]), we observed a 10-fold increase in the BM frequency of CD34^−^KSL pHSCs in aged C57BL/6 mice. We found that functional LT-HSCs also expand in the BM with age, although by a more modest 2.9-fold ([Table 1](#tbl1){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}C). Similar increases were seen in the frequency of total functional HSCs (including ST-, IT-, and LT-HSCs). However, because we did not directly compete single young HSCs against single aged HSCs, we cannot draw conclusions about age-related changes to the potency of HSCs (i.e., level of donor chimerism). Several direct comparisons using bulk HSC transplantations assays have suggested that young HSCs outcompete aged HSCs ([@bib5]). Such an experiment is difficult using our current methodology but could be achieved by combining our approaches with *in vivo* cellular barcoding technology ([@bib15]).

Although absolute numbers of functional HSCs increased in the BM with age, functionally multipotent HSCs become less frequent within the pHSC compartment due to a large increase in MyRPs/MySCs. Besides the 13-fold increase in MyRPs/MySCs (all reconstituting types in primary recipients) within the aged BM, non-reconstituting pHSCs also increased nearly 16-fold with age ([Table 1](#tbl1){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}C), which combined are responsible for the "dilution" of functional HSCs within the pHSC compartment. Through clonal analysis of HSC aging, we were able to distinguish the expansion of myeloid-restricted MyRPs from the myeloid bias of multipotent HSCs.

Accumulation of MyRPs/MySCs with age suggests the possibility that the myeloid-bypass pathway ([@bib21]) is the major route of HSC differentiation. Correspondingly, our single-cell secondary transplantation assays ([Figure S3](#mmc1){ref-type="supplementary-material"}) suggested that ST-MyRP accumulation may at least in part be driven by cell division of LT-HSCs. Our analysis also highlights that while the frequency and composition of the pHSC compartment changes dramatically with age, the frequency of mature cell types within the hematopoietic system only changes gradually ([Figure S1](#mmc1){ref-type="supplementary-material"}C). This disconnect between HSC/MyRP frequencies and mature blood cell frequencies is likely due to still poorly defined tissue homeostatic mechanisms. Interestingly, "clonal hematopoiesis", the clonal dominance of certain somatically acquired clonal mutations in human PB, has recently been strongly correlated with age and is now considered to be a precursor (or "pre-leukemic") state to hematological malignancies ([@bib7], [@bib10], [@bib11], [@bib17]). Our data suggest that we must consider as potential origins of clonal hematopoiesis not only HSCs but also self-renewing MyRPs/MySCs.

One of the most surprising findings from our single-cell transplantation assays was the identification of latent-HSCs, a subpopulation of aged pHSCs that displayed myeloid-restricted output over 24 weeks in primary recipients but then displayed a five blood-lineage HSC phenotype following transplantation into secondary recipients. This delay in the functional output of latent-HSCs suggests that we may need to re-evaluate current methods to assay HSC function. Surprisingly, latent-HSCs were more frequent within the aged BM than LT-HSCs, found at ∼82 per 10^6^ BM cells (compared to 21 per 10^6^ BM cells for LT-HSCs) ([Figure 3](#fig3){ref-type="fig"}C). A better understanding of the latent-HSC phenotype could help to develop therapeutic strategies to "rebalance" hematopoiesis in aged individuals. An important next step for this will be the development of methods to prospectively isolate latent HSCs for molecular analysis.

While the mechanistic basis of the latent-HSC phenomenon remains to be determined, several hypotheses are apparent. First, the weak differentiation output is reminiscent of the recently described activity of native HSCs ([@bib19]), suggesting primary transplantation stress may be insufficient to induce differentiation and hematopoietic system reconstitution. Latent-HSCs may have multipotent potential in primary recipients but only display a limited subset of their potential in PB cell output. Second, the repression of lymphoid output by MySCs described by [@bib3] may be eroded with age and could result in multipotent output in secondary recipients. Genetic and epigenetic alterations are closely correlated with phenotypic and functional changes to HSCs and could be responsible. Third, our transplantation assays used young mice as recipients, so it is possible that transfer of aged cells into a young BM microenvironment could lead to "rejuvenation" or "conversion" of MySCs into transplantable multipotent HSCs through non-cell-autonomous mechanisms. Further experimentation is warranted to test such hypotheses and determine the physiological relevance of latent-HSCs. Nonetheless, the existence of latent-HSCs in aged mice not only leads us to reconsider the HSC definitions and assay systems but also opens up a new paradigm in HSC biology.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Biotin anti-CD4eBioscienceCat\#13-0041-85, RRID:[AB_466326](nif-antibody:AB_466326){#intref0010}Biotin anti-CD8eBioscienceCat\# 13-0081-86, RRID:[AB_466348](nif-antibody:AB_466348){#intref0015})Biotin anti-B220/CD45RAeBioscienceCat\# 36-0452-85, RRID:[AB_469753](nif-antibody:AB_469753){#intref0020}Biotin anti-TER-119eBioscienceCat\# 13-5921-85, RRID:[AB_466798](nif-antibody:AB_466798){#intref0025}Biotin anti-Ly-6G/Ly-6C (RB6-8C5)eBioscienceCat\# 13-5931-85, RRID:[AB_466801](nif-antibody:AB_466801){#intref0030}Biotin anti-CD127 (A7R34)eBioscienceCat\# 13-1271-85, RRID:[AB_466589](nif-antibody:AB_466589){#intref0035}Biotin anti-CD3e Monoclonal Antibody (145-2C11)eBioscienceCat\# 13-0031-85, RRID:[AB_466320](nif-antibody:AB_466320){#intref0040}Biotin anti-CD19 (MB19-1)eBioscienceCat\# 13-0191-85, RRID:[AB_466385](nif-antibody:AB_466385){#intref0045}Biotin anti-IgM (II/41)eBioscienceCat\# 13-5790-85, RRID:[AB_466676](nif-antibody:AB_466676){#intref0050}Biotin anti-CD5 (53-7.3)eBioscienceCat\# 13-0051-85, RRID:[AB_466340](nif-antibody:AB_466340){#intref0055}APC anti-c-Kit (2B8)eBioscienceCat\# 17-1171-82, RRID:[AB_469430](nif-antibody:AB_469430){#intref0060}PE/Cy7 anti-c-Kit (2B8)eBioscienceCat\# 25-1171-82, RRID:[AB_46964](nif-antibody:AB_46964){#intref0065}Pacific Blue-c-Kit (2B8)BiolegendCat\# 105820, RRID:[AB_493476](nif-antibody:AB_493476){#intref0070}Alexa Fluor 700 anti-CD34 (RAM34)eBioscienceCat\# 56-0341-82, RRID:[AB_493998](nif-antibody:AB_493998){#intref0075}FITC anti-CD34 (RAM34)eBioscienceCat\# 11-0341-85, RRID:[AB_465022](nif-antibody:AB_465022){#intref0080}Brilliant Violet 421 anti-CD150 (TC15-12F12.2)BioLegendCat\# 115943, RRID:[AB_2650881](nif-antibody:AB_2650881){#intref0085}APC anti-CD150 (TC15-12F12.2)BioLegendCat\# 115910, RRID:[AB_493460](nif-antibody:AB_493460){#intref0090}Brilliant Violet 421 anti-CD41 (MWReg30)BioLegendCat\# 133912, RRID:[AB_2650893](nif-antibody:AB_2650893){#intref0095}FITC anti-CD41 (MWReg30)eBioscienceCat\# 11-0411-85, RRID:[AB_763483](nif-antibody:AB_763483){#intref0100}PE/Cy7-conjugated anti Ly-6A/E (Sca-1) (D7)eBioscienceCat\# 25-5981-82, RRID:[AB_469669](nif-antibody:AB_469669){#intref0105}PerCP/Cy5.5 anti-Ly-6A/E (Sca-1) (D7)eBioscienceCat\# 45-5981-82, RRID:[AB_914372](nif-antibody:AB_914372){#intref0110}Alexa Fluor 700 anti-Ly-6A/E (Sca-1) (D7)eBioscienceCat\# 56-5981-82, RRID:[AB_657836](nif-antibody:AB_657836){#intref0115}Brilliant Violet 510 anti-Ly-6A/E (Sca-1) (D7)BioLegendCat\# 108129, RRID:[AB_2561593](nif-antibody:AB_2561593){#intref0120}PE/Cy7 anti-Ly-6A/E (Sca-1) (D7)BioLegendCat\# 122514, RRID:[AB_756199](nif-antibody:AB_756199){#intref0125}APC/Cy7-CD48 (HM48-1)BioLegendCat\# 103432, RRID:[AB_2561463](nif-antibody:AB_2561463){#intref0130}APC anti-CD135 (Flt3) (A2F10)eBioscienceCat\# 17-1351-82, RRID:[AB_10717261](nif-antibody:AB_10717261){#intref0135}PE anti-CD135 (Flt3) (A2F10)eBioscienceCat\# 12-1351-83, RRID:[AB_465860](nif-antibody:AB_465860){#intref0140}PerCP/eFluor 710 anti-CD135 (Flt3) (A2F10)eBioscienceCat\# 46-1351-82, RRID:[AB_10733393](nif-antibody:AB_10733393){#intref0145}PE/Cy7 anti-CD127 (IL7Ralpha) (A7R34)BioLegendCat\# 135014, RRID:[AB_1937265](nif-antibody:AB_1937265){#intref0150}PE anti-CD16/32 (93)BioLegendCat\# 101308, RRID:[AB_312807](nif-antibody:AB_312807){#intref0155}FITC anti-CD16/32 (93)BioLegendCat\#101306, RRID:[AB_312805](nif-antibody:AB_312805){#intref0160}Streptavidin-APC/Cy7BioLegendCat\# 405208Streptavidin-APC/eFluor 780eBioscienceCat\# 47-4317-82, RRID:[AB_10366688](nif-antibody:AB_10366688){#intref0165}Streptavidin-Brilliant Violet 605BioLegendCat\# 405229PE-Cy7 anti-CD45.1BioLegendCat\# 110730, RRID:[AB_1134168](nif-antibody:AB_1134168){#intref0170}Pacific Blue anti-CD45.2BioLegendCat\# 109820, RRID:[AB_492872](nif-antibody:AB_492872){#intref0175}FITC anti-Ly-6G (Gr-1) (RB6-8C5)eBioscienceCat\# 11-5931-85, RRID:[AB_465315](nif-antibody:AB_465315){#intref0180})FITC anti-CD11b (M1/70)eBioscienceCat\# 11-0112-41, RRID:[AB_11042156](nif-antibody:AB_11042156){#intref0185}APC-eFluor780 CD45R (B220) (RA3-6B2)eBioscienceCat\# 47-0452-82, RRID:[AB_1518810](nif-antibody:AB_1518810){#intref0190}APC anti-CD3 (17A2)BiolegendCat\# 100236, RRID:[AB_2561456](nif-antibody:AB_2561456){#intref0195}APC anti-CD4 (RM4-5)eBioscienceCat\# 17-0042-83, RRID:[AB_469324](nif-antibody:AB_469324){#intref0200}APC anti-CD8 (53-6.7)eBioscienceCat\# 17-0081-83, RRID:[AB_469336](nif-antibody:AB_469336){#intref0205}APC anti-TER-119 (TER-119)eBioscienceCat\# 17-5921-83, RRID:[AB_469474](nif-antibody:AB_469474){#intref0210}eFluor 450 anti-CD41a (MWReg30)eBioscienceCat\# 48-0411-82, RRID:[AB_1582238](nif-antibody:AB_1582238){#intref0215}FITC anti-CD42a (Xia.B4)EMFRET AnalyticsCat\# M051-1**Critical Commercial Assays**Anti-APC MicroBeadsMiltenyi BiotecCat\#130-090-855, RRID:[AB_244367](nif-antibody:AB_244367){#intref0220}LS columnsMiltenyi BiotecCat\#130-042-401**Experimental Models: Organisms/Strains**Mouse: Female C57BL/6-Ly5.2 NCrSlcJapan SLC<http://jslc.co.jp/english/index2.htm>Mouse: Male C57BL/6-Ly5.1/5.2-F1Sankyo-Lab ServiceN/AMouse: Male Kusabira-Orange transgenic mouse (KuO mouse)Nakauchi Laboratory at University of Tokyo[https://doi.org/10.1016/j.bbrc.2013.05.017](10.1016/j.bbrc.2013.05.017){#intref0230}

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Hiromitsu Nakauchi (<nakauchi@stanford.edu>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

Female C57BL/6-Ly5.2 (Ly5.2) and male C57BL/6-Ly5.1/5.2-F1 (Ly5.1/Ly5.2-F1) mice were purchased from Japan SLC (Shizuoka, Japan) and Sankyo-Lab Service (Tsukuba, Japan), respectively. Eight- to twelve-week-old male Kusabira-Orange mice (KuO mice) served as young donors. Twenty to twenty-four month-old male mice served as aged donors. Eight- to twelve-week-old Ly5.2 female mice served as recipients. All mice were housed in a specific pathogen-free (SPF) condition and were carefully observed by staffs. Animal experiments were approved by the Animal Care and Use Committee, Institute of Medical Science, University of Tokyo.

Method Details {#sec4.4}
--------------

### Hematopoietic stem/progenitor cell analysis in untransplanted mice {#sec4.4.1}

Bone marrow cells were isolated from tibia, femur and pelvis of male young (8-12 week) and aged (20-24 month) mice and were stained with antibodies as detailed below. Biotin antibody staining was initially performed for 30 minutes, followed by a PBS wash, and a 90-minute stain with the remaining antibodies (all at 4°C). Samples were washed with PBS before analysis. Bone marrow analysis was performed on a FACS AriaII cell sorter (BD Biosciences). Collected data were analyzed with FlowJo software (Tree Star, Ashland, OR). Bone marrow cell type frequencies were calculated from 2x10^6^ live lineage^-^ BM cells per mouse.

Phenotypic cell-surface markers to stain for hematopoietic stem/progenitor cells (including HSCs, MPPs, LMPPs) were stained with a lineage cocktail (biotinylated-CD4, CD8, B220, Gr-1, TER-119 and CD127), FITC-CD34, APC-CD150, Brilliant Violet 421-CD41, PE/Cy7-c-Kit, Brilliant Violet 510-Sca-1, and PE-Flt3 and streptavidin-Brilliant Violet 605.

Phenotypic cell-surface markers to stain for myeloid progenitors (including CMPs, MEPs, GMPs and MkPs) were detected using a lineage cocktail (biotinylated-CD4, -CD8, -B220/CD45RA, -Gr1, -TER-119, -CD127, -CD3, -CD19, and -IgM), FITC-CD34, PE-CD16/32, APC-CD150, Brilliant Violet-CD41, PE/Cy7-c-Kit, Brilliant Violet 510-Sca-1 and streptavidin-APC-Cy7 or -APC/eFluor780.

Phenotypic cell-surface markers to stain for CLP were detected using a lineage cocktail (biotinylated-CD4, -CD8, -B220/ CD45RA, -Gr1, -TER-119, -CD3, and -CD5), PE-Flt3, PE/Cy7-CD127, APC-c-Kit, and Brilliant Violet 510-Sca-1 antibodies, and streptavidin-APC/Cy7 or -APC/eFluor780.

### Complete blood count analysis {#sec4.4.2}

Peripheral blood samples were collected from the retro-orbital venous plexus into capillary tubes filled with powered EDTA. Complete blood count analysis was performed using an automated cell counter (Celltec α, Nihon Koden).

### Single cell sorting and transplantation {#sec4.4.3}

Single cell sorting and transplantation was performed as described previously ([@bib21]). Bone marrow cells were isolated from tibia, femur and pelvis of male young (8-12 week) and aged (20-24 month) KuO mice and were stained for 30 minutes with APC-c-Kit and c-Kit positive cells were enriched using anti-APC magnetic bead (15 minute incubation) and LS columns (Miltenyi Biotec). These cells were then stained for 30 minutes with a lineage cocktail (biotinylated-CD4, -CD8, -B220/CD45RA, -TER-119, -Gr-1, and -CD127). Finally, cells were stained for 90 minutes with Alexa Fluor 700-CD34, Brilliant Violet 421-CD150, FITC-CD41, PE-Cy7-Sca-1 and streptavidin-APC/Cy7 or APC/eFluor 780 and were sorted into 96-well plate with PBS containing 4% FBS on FACS AriaII cell sorted (special order system). For single-cell sorting, the presence of one cell per well was verified under an inverted microscope. Whole bone marrow cells, which served as competitor cells, were isolated from male Ly5.1/Ly5.2-F1 mice and 2 × 10^5^ nucleated cells were transferred into 96-well plate wells. Single KuO cells and competitor cells were transplanted together into lethally irradiated Ly5.2 mice (given two doses of 4.9 Gy, 4 hours apart).

Of the 451 primary recipient mice, 30 died during follow-up, and were eliminated from analyses. Secondary transplantation using cells from femora and tibiae, pelvis, (upper forelimb, and backbone) of the primary recipients were performed to assess self-renewal activity when some myeloid lineages were detected in PB at 24 week after primary transplant. For secondary transplantation, 10^7^ whole BM cells were injected into young female lethally-irradiated (given two doses of 4.9 Gy, 4 hours apart) mice (1-5 per primary recipient).

### Secondary single cell transplantation {#sec4.4.4}

Secondary single cell transplantation using primary recipients that had been transplanted with single cells of young phenotypic HSCs was performed to assess division patterns of transplanted single cell in the primary recipients. At 20 weeks or more after primary transplant, bone marrow cells were isolated from tibia, femur and pelvis, upper forelimb and backbone and were stained with antibodies and sorted using the same protocol as the single cell staining and transplantation section. Single cells of Fractions 1, 2, or 3 were transplanted into young female lethally irradiated mice. Simultaneously, whole bone marrow cells were transplanted into mice (using the same method above) to assess self-renewal activity of the transplanted single cells in the primary recipients.

### Peripheral blood (PB) analysis {#sec4.4.5}

PB was collected from the retro-orbital venous plexus into capillary tubes containing a minimal volume of 10 mM EDTA in water. After erythrocyte lysis with aqueous 140 mM ammonium chloride, cells were stained for 30 minutes with PE/Cy7-CD45.1, Pacific Blue-CD45.2, FITC-Gr-1, FITC-Mac-1, APC/eFluor780-CD45RA/B220, APC-CD3. For analysis of erythrocytes and platelets, one ml of collected blood was stained with APC-TER-119 and eFluor450-CD41. The percentage of chimerism of neutrophils/monocytes, B cells, T cells, erythrocytes, or platelets was defined as the percentage of KuO^+^ cells among CD45.1^+^ B220^-^CD3^-^Gr-1^+^ Mac1^+^ cells, CD45.1^+^Gr-1^-^Mac-1^-^CD3^-^B220^+^ cells, CD45.1^+^Gr-1^-^Mac-1^-^B220^-^CD3^+^ cells, CD41^-^TER-119^+^ cells, or TER-119^-^CD41^+^ cells. The FSC^high^ gate and FSC^low^ gate were used for analysis of erythrocytes and platelets, respectively. PB analysis was performed on a Gallios (Beckman Coulter, Fullerton, CA, USA), FACSCanto, or FACS AriaII cell sorter (BD Biosciences). Collected data were analyzed with FlowJo software (Tree Star, Ashland, OR). Recipient mice were defined as reconstituted when at least one type of mature blood lineage contained donor-derived KuO^+^ cells at 0.005% or more, to avoid overlooking reconstitution especially of platelets and erythrocytes. PB chimersim was calculated based on 30,000-50,000 leukocytes, 20,000-50,000 platelets, and 500,000 erythrocytes, per mouse/time point.

### Hematopoietic stem/progenitor cell staining for frequency analysis in transplanted mice {#sec4.4.6}

We analyzed BM cells of primary and secondary recipients to determine the frequency of KuO^+^ phenotypic stem and progenitor cell population. Whole bone marrow cells were isolated from tibia, femur, pelvis, (upper forelimb bones, and backbones) of recipient mice and were stained with antibodies, as detailed below. Biotin antibody staining was initially performed for 30 minutes, followed by a PBS wash, and a 90-minute stain with the remaining antibodies (all at 4°C). Samples were washed with PBS before analysis. Bone marrow analysis was performed on a Gallios (Beckman Coulter, Fullerton, CA, USA), FACSCanto, or FACS AriaII cell sorter (BD Biosciences). Collected data were analyzed with FlowJo software (Tree Star, Ashland, OR). Bone marrow cell type frequencies were calculated from 2x10^6^ live lineage^-^ BM cells per mouse.

Phenotypic cell-surface markers to stain for hematopoietic stem/progenitor cells (including HSCs, MPPs, LMPPs) were stained with a lineage cocktail (biotinylated-CD4, CD8, B220, Gr-1, TER-119 and CD127), Alexa Fluor 700-CD34, Brilliant Violet 421-CD150, FITC-CD41, PE/Cy7-c-Kit, PerCP/Cy5.5-Sca-1, and APC-Flt3 and streptavidin-APC-Cy7 or -APC/eFluor780; or Alexa Fluor 700-CD34, PE/Cy7-CD150, Pacific Blue-CD41, PE/Cy7-c-Kit, Brilliant Violet 510-Sca-1, and PerCP/eFluor 710-Flt3 and streptavidin-APC-Cy7 or -APC/eFluor780.

Phenotypic cell-surface markers to stain for myeloid progenitors (including CMPs, MEPs, GMPs and MkPs) were detected using a lineage cocktail (biotinylated-CD4, -CD8, -B220/CD45RA, -Gr1, -TER-119, -CD127, -CD3, -CD19, and --IgM), Alexa Fluor 700-CD34, FITC-CD16/32, PE/Cy7-CD150, Brilliant Violet 410- or eFluor 450-CD41, APC-c-Kit, Brilliant Violet 510-Sca-1 antibodies, and streptavidin-APC-Cy7 or -APC/eFluor780.

Phenotypic cell-surface markers to stain for CLP were detected using a lineage cocktail (biotinylated-CD4, -CD8, -B220/ CD45RA, -Gr1, -TER-119, -CD3, and -CD5), APC-Flt3, PE/Cy7-CD127, Pacific Blue-c-Kit, and Alexa Fluor 700-Sca-1 antibodies, and streptavidin-APC/Cy7 or -APC/eFluor780; or APC-Flt3, PE/Cy7-CD127, Pacific Blue-c-Kit, and Alexa Fluor 700-Sca-1 antibodies, and streptavidin-APC/Cy7 or -APC/eFluor780 or PerCP/eFluor 710-Flt3, APC/Cy7-CD127, Pacific Blue-c-Kit, and Alexa Fluor 700-Sca-1 antibodies, and streptavidin-APC/Cy7 or -APC/eFluor780; or APC-Flt3, PE/Cy7-CD127, PE/Cy7-c-Kit, and Brilliant Violet 510-Sca-1, and streptavidin-Brilliant Violet 605.

Quantification and Statistical Analyses {#sec4.5}
---------------------------------------

Chimerism comparisons were performed using unpaired t test ([Figure 2](#fig2){ref-type="fig"}C). Statistical analysis in [Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C were performed with Mann-Whitney U-test (two-tail). Statistical analysis was performed using chi-square test ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Multiple comparison in each of young LT-HSCs, aged LT-HSCs and latent HSCs were calculated using SNK test ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

Data and Software Availability {#sec4.6}
------------------------------

The software for data analysis included Flowjo, GraphPad Prism, and Microsoft Excel.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S4 and Tables S1--S3Document S2. Article plus Supplemental Information
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